Related Experiment Videos
Platelets: is aspirin sufficient or must we know how to pronounce abciximab?
William T Brinkman1, Thomas T Terramani, Sasan Najibi
1Department of Surgery, Emory University School of Medicine, Atlanta, GA 30322, USA.
Insights
Antiplatelet therapy is crucial for managing systemic vascular disease, reducing cardiovascular events, and maintaining graft patency. Future strategies aim for simultaneous blockade of multiple platelet pathways for enhanced safety and efficacy.
Area of Science:
- Vascular Surgery
- Cardiology
- Pharmacology
Background:
- Vascular disease is a systemic condition requiring pharmacologic management to reduce cardiovascular morbidity and mortality.
- Antiplatelet agents are vital for preventing cerebrovascular and coronary events.
- These medications also maintain patency of peripheral vessels and grafts after interventions.
Purpose of the Study:
- To review current recommendations for antiplatelet therapy in peripheral vascular disease.
- To discuss the role of antiplatelet treatments in reducing future cardiovascular events.
- To explore future directions in antiplatelet therapy, including multi-pathway inhibition.
Main Methods:
- Review of current literature and clinical guidelines.
- Analysis of the efficacy of aspirin, thienopyridines, and GP IIb/IIIa inhibitors.
- Discussion of emerging strategies for antiplatelet drug development.
Main Results:
- Antiplatelet therapy significantly reduces cerebrovascular and coronary events.
- These agents are effective in maintaining peripheral vessel and graft patency.
- Current recommendations focus on established antiplatelet drugs for vascular disease management.
Conclusions:
- Systemic vascular disease necessitates comprehensive antiplatelet strategies.
- Future antiplatelet therapies will likely involve simultaneous blockade of multiple platelet activation pathways.
- Targeted antiplatelet medications offer improved safety and efficacy in managing vascular disease.
Abstract:
Although vascular disease may present with symptoms that are representative of a focal exacerbation of atherosclerosis, it is inherently a systemic disease. Consequently, vascular surgeons must be capable of recommending to their patients pharmacologic approaches that will decrease future risk of cardiovascular-related morbidity and death. Antiplatelet treatments, in particular, have been shown to reduce future cerebrovascular and coronary events. Moreover, these medications have utility in maintaining peripheral vessel and graft patency after surgical bypass, endarterectomy, or percutaneous translumenal angioplasty. The future of optimal antiplatelet therapy will consist of strategies that block multiple platelet activation pathways simultaneously. Moreover, the use of directed antiplatelet medications promises more effective control of platelet physiology with a concomitant increase in safety. The authors review herein current recommendations for the use of aspirin, thienopyridines, and GP IIb/IIIa inhibitors in patients with peripheral vascular disease.